Biotech Values

[DewDiligence]

IMUX—(+60%/AH)—climbs on the COVID-19 bandwagon:

https://www.prnewswire.com/news-releases/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients-301044640.html

Immunic, Inc…today reported that its lead asset, IMU-838…was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with coronavirus disease 2019 (COVID-19). In cellular assays, IMU-838 demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with IMU-838 dosing regimens studied in ongoing and previous clinical trials. These positive results have encouraged Immunic to prepare a clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 and potential other, future viral pandemics.

Caveat emptor.